Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has begun dosing the first patients in a Phase I/II UTI clinical trial evaluating RECCE® 327 at Scientia Clinical Research.
The company is dosing patients at a faster infusion rate than the recently completed Phase I clinical trial.
RCE expanded the trial to the Scientia Clinical Research site to accelerate patient recruitment and broaden the potential patient population.
The study is tracking to primary end-points, with the remaining subjects to be dosed this week at Scientia Clinical Research, with expected data read-outs in H2 2023.